Investigators probing the alleged Rs 842-crore Delhi health department equipment and medicine procurement scam are examining people whose names were allegedly used to create companies that secured government tenders, according to a report by Jagran – New Delhi published on November 7.
The investigation is also tracing payments of about Rs 839 crore made to five key companies linked to the main accused, Rajiv Rangila. Investigators are examining the companies’ bank accounts, transactions with one another and the eventual recipients of the money, the report said.
The inquiry is focused on whether employees and domestic helpers whose documents were allegedly used to make them directors knew about the companies, government tenders and payments conducted in their names. Investigators are also trying to establish who actually controlled the companies and managed the process from securing tenders to receiving payments.
According to the report, the role of Sunil Kumar and Laxman Singh, associated with M Sahib and Sons Private Limited, is being examined. The investigation is looking into the company’s procurement activities, its business relationships with F-Med Devices and other companies, and the financial transactions connected with them. It is also examining whether the individuals had knowledge of the companies’ actual business and whether they received any financial benefit.
The case also includes the reported use of former Rangila employee Gyan Chand’s documents. The report said investigators are examining allegations that his documents were misused to make him a director of a company. The inquiry will determine whether the named individuals were participants, beneficiaries or people whose identities were used without their knowledge; the supplied report does not establish the outcome for any of them.
The investigation follows allegations of irregularities in the purchase of medical equipment and medicines for Delhi’s health department. A related concern cited in the report is that, despite payments, records or evidence showing that medicines and equipment reached hospitals have not been found in some parts of the case. That issue places procurement documentation, delivery records and payment trails at the centre of the inquiry.
The reported payment figure of about Rs 839 crore represents the amount linked to five major companies associated with Rangila, while the wider alleged scam has been described as involving Rs 842 crore. The difference between the two figures reflects the scope described in the report and does not by itself establish the final loss to the exchequer.
The next stage of the investigation is expected to focus on the ownership and operation of the companies, the movement of funds after government payments and the role, if any, of the individuals listed as directors. The report did not state that the investigation had reached a final conclusion or that liability had been established against all the people being examined.
